Durham
Juul to pay US state $40 million for targeting teens with e-cigarettes
Electronic cigarette giant Juul Labs Inc will pay $40m to North Carolina and take more action to prevent underage use and sales, according to a landmark United States legal settlement announced on Monday after years of accusations that the company had fueled an explosion in teen vaping. A state judge accepted the first-of-its-kind agreement with a US state. North Carolina Attorney General Josh Stein had sued Juul, accusing it of employing unfair and deceptive marketing practices that targeted young people to use its vaping products, which deliver addictive nicotine. As part of the agreement, Juul will not advertise to anyone under 21 in North Carolina and will limit sales amounts of Juul products online to any state residents. It will also sell its products only behind counters at retailer...
US election: Republicans hold back Democrats, narrowing path to Senate control
The battle for power in the Senate tightened into Wednesday as Democrats picked up a seat in Colorado, but suffered a setback in Alabama, and Republicans held their own in high-profile races in South Carolina, Iowa, Texas and Kansas, dramatically narrowing the political map. Republicans fought to retain their Senate majority by turning back a surge of Democrats challenging allies of President Donald Trump, and the Democrats’ various paths to seizing control were growing more limited. With several contests still too early to call, and one Georgia race heading to a January runoff, the final verdict is expected to drag on. Democrats gained a seat when ex-Gov. John Hickenlooper ousted GOP Sen. Cory Gardner in Colorado, a must-win to flip the Senate, but couldn’t hold on in Alabama, where forme...
British lawmakers write Commonwealth over killings in Nigeria
Thirteen members of the House of Lords, United Kingdom, have expressed concern over the killings by Boko Haram insurgents in the North-East and Fulani herdsmen in the Middle Belt region. The upper house of parliament members said the failure of the Federal Government to protect Nigerians was a breach of the Commonwealth Charter. They requested the Commonwealth to raise the killings with its Ministerial Action Group. This was contained in a letter to the Secretary-General of the Commonwealth, Patricia Scotland, dated September 14, co-signed by Baroness Cox, Baroness Kennedy, Jim Shannon, Fiona Bruce, former Archbishop of Canterbury, Lord Williams and 14 others. They cited a report by the UK All-Party Parliamentary Group for International Freedom of Religion or Belief, which accused unnamed ...
Britain secures early access to promising vaccine candidates
The British government on Friday announced that it had secured early access to 90 million doses of two new promising vaccine candidates. British citizens will receive early access to 90 million doses of the two COVID-19 vaccine candidates should they prove safe and effective. By far, the British government has secured access to six different vaccine candidates as part of the government’s strategy to build a portfolio of promising new vaccines should any be found to be safe and effective. The government has also agreed in principle to co-fund a global clinical trial with the Janssen Pharmaceutical Companies of Johnson and Johnson to establish how effective their vaccine could be in providing long-term immunity against COVID-19. The next phase of Janssen’s clinical trials is expected to begi...
Pfizer, BioNTech dose U.S first participants of trial coronavirus vaccine
Pfizer Inc. and BioNTech SE announced on Wednesday, May 6, 2020, that the first participants have been dosed in the U.S in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development program, and the dosing of the first cohort in Germany was completed last week. The Phase 1/2 study is designed to determine the safety, immunogenicity and optimal dose level of four mRNA vaccine candidates evaluated in a single, continuous study. The dose level escalation portion (Stage 1) of the Phase 1/2 trial in the U.S will enrol up to 360 healthy subjects into two age cohorts (18-55 and 65-85 years of age). The first subjects immunized in Stage 1 of the study will be healthy adults 18-55 years of age. Older adults will only be immunized with ...
